U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H17N3
Molecular Weight 215.2942
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRAMAZOLINE

SMILES

C1CN=C(NC2=C3CCCCC3=CC=C2)N1

InChI

InChIKey=QQJLHRRUATVHED-UHFFFAOYSA-N
InChI=1S/C13H17N3/c1-2-6-11-10(4-1)5-3-7-12(11)16-13-14-8-9-15-13/h3,5,7H,1-2,4,6,8-9H2,(H2,14,15,16)

HIDE SMILES / InChI

Molecular Formula C13H17N3
Molecular Weight 215.2942
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Tramazoline is a sympathomimetic drug that is used in the form of tramazoline hydrochloride in nasal decongestant preparations. Tramazoline is an α-adrenergic receptor agonist that inhibits secretion of nasal mucus.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
16.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Spray-Tish

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended dose for adults and children six years of age and over is 1 to 2 sprays into each nostril up to four times daily as required.
Route of Administration: Nasal
In Vitro Use Guide
Binding affinity of Tramazoline against Alpha-2 adrenergic receptor measured as the ability to inhibit the specific [3H]clonidine binding (0.4 nM) to rat isolated brain membranes by 50% was 16 nM.
Substance Class Chemical
Record UNII
SLE31693IV
Record Status Validated (UNII)
Record Version